Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

BACKGROUND: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016. In the year following generic entry, imatinib’s price is expected to drop 70% to 90%. We hypothesized that...

Descripción completa

Detalles Bibliográficos
Autores principales: Padula, William V., Larson, Richard A., Dusetzina, Stacie B., Apperley, Jane F., Hehlmann, Rudiger, Baccarani, Michele, Eigendorff, Ekkehard, Guilhot, Joelle, Guilhot, Francois, Mahon, Francois-Xavier, Martinelli, Giovanni, Mayer, Jiri, Müller, Martin C., Niederwieser, Dietger, Saussele, Susanne, Schiffer, Charles A., Silver, Richard T., Simonsson, Bengt, Conti, Rena M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948567/
https://www.ncbi.nlm.nih.gov/pubmed/26944912
http://dx.doi.org/10.1093/jnci/djw003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948567/
https://www.ncbi.nlm.nih.gov/pubmed/26944912
http://dx.doi.org/10.1093/jnci/djw003

Ejemplares similares